TrioBiotics Pharma AG
Triton Biopharma AG: Raymond Schinazi joins company as a Board Member
Triton Biopharma AG / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Zug, Switzerland – January 23rd, 2009 – TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced the appointment of Dr. Raymond F. Schinazi, Ph.D., D.Sc., to the Board of Directors for Triton BioPharma AG. Dr. Raymond Schinazi is presently a Professor of Pediatrics and Chemistry and Director of the Laboratory of Biochemical Pharmacology at Emory University. Professor Schinazi received his Ph.D. in Chemistry in 1976 from the University of Bath, England, and completed post-doctoral training in Pharmacology at Yale University and in Virology/Immunology at Emory University. He serves as the Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and co-Director of the Virology/Drug Discovery Core for the NIH sponsored Emory University Center for AIDS Research (CFAR). In 2006, he received an honorary D.Sc. from Bath University for his research accomplishments in the field of HIV and biotechnology. In 2008, the Dean’s Distinguished Faculty Lecture and Award, the most prestigious and celebratory honor for a faculty member of Emory University School of Medicine, was bestowed upon Dr. Schinazi. He also served on the Presidential Commission on AIDS. Dr. Schinazi is the founder of several biotechnology companies focusing on antiviral drug discovery and development, and has been pivotal in the discovery and development of successful anti-HIV and anti-hepatitis drugs. Six of his drug discoveries are now approved by the US Food and Drug Administration, or are in clinical development, including Lamivudine, the key anti-HIV drug used in the majority of AIDS cocktails today. His inventions now sell more than US$2.0 billion per year and more than 80% of the HIV infected individuals take at least one of the drugs he invented. He has published over 430 peer-reviewed papers and 7 books, and holds more than 70 US patents. 'We are excited and honored to have Dr. Schinazi join our Board as a key member', said Angelo Boujos, Chairman and CEO of Triton BioPharma AG. Mr. Boujos continued, 'He brings tremendous knowledge of the pharmaceutical industry and its regulatory environment, which will be invaluable in guiding Triton’s product development programs.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. Contact: Investor Relations Europe: Milestone Media AG, Zug, Switzerland Phone: +41 (0)41 5000 769 Fax: +41 (0)41 5000 728 E-mail: info@milestonemedia.ch For more information, visit www.tritonbiopharma.com 23.01.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden